NG9 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
NGS Growth And Favorable Mix ShiftSustained NGS growth and a material mix shift toward higher‑complexity assays increase revenue per test and long‑run margin potential. As precision oncology adoption expands, NGS scale supports durable competitive advantage, stronger per‑unit economics, and diversification of clinical revenue.
Improving Cash Generation And LiquidityOperating cash flow turning positive and management guidance toward full‑year free cash flow positivity signal improved cash conversion. Durable improvement in cash generation reduces dependency on capital markets, supports reinvestment in sales and R&D, and strengthens ability to execute strategic initiatives over months.
Board Hire Enhances Data/AI Strategic CapabilityAdding a director with oncology real‑world data and AI leadership strengthens governance over data products and analytics strategy. This enhances the company's ability to monetize RWD, bolster pharma services, and embed AI into diagnostics—an enduring edge as oncology care shifts toward data‑driven decisioning.
Bears Say
Persistent Unprofitable OperationsDespite revenue growth, sustained negative net margins and a history of negative free cash flow indicate the cost base has not fully scaled to profitable operations. This structural profitability gap requires continued margin expansion or recurring external funding and limits durable shareholder value creation.
Payer And Reimbursement UncertaintyLong lead times for commercial payer coverage can delay revenue realization from new product launches and weigh on margins. Reimbursement uncertainty is a structural industry constraint that can materially slow scale and cash conversion of high‑value diagnostics over multiple quarters to years.
Nonclinical (pharma Services) WeaknessA decline in pharma and nonclinical services reduces revenue diversification and increases exposure to clinical volumes for growth. If pharma demand remains soft, it can amplify cyclicality, limit margin stability, and make overall revenue less resilient to healthcare macro trends.
NeoGenomics News
NG9 FAQ
What was NeoGenomics’s price range in the past 12 months?
Currently, no data Available
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is CHF1.49B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Aug 05, 2026 which is in 37 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Apr 28, 2026. The company reported CHF0.008 earnings per share for the quarter, beating the consensus estimate of CHF0.005 by CHF0.003.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.03.
How many shares outstanding does NeoGenomics have?
Currently, no data Available
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of CHF0.008 in its last earnings report, beating expectations of CHF0.005. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in CH:NG9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeoGenomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF12.12 (― Downside)
CHF12.12 (― Downside)
Insider Transactions
Sold Shares
Worth CHF96.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.90%
12-Months-Change
Fundamentals
Return on Equity
-11.82%
Trailing 12-Months
Asset Growth
-15.92%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
NG9 Company Deck
NG9 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial trajectory: consistent double-digit top-line growth, strong NGS performance (+26% YoY) with favorable mix shift (NGS now ~1/3 of clinical revenue), adjusted EBITDA expansion (+27% YoY), early commercial and reimbursement wins (PanTracer MolDX approval, RaDaR ST launch), and an increase to full-year revenue guidance. Offsetting risks include a meaningful nonclinical decline (-15% YoY), first-quarter gross margin headwinds (–80 bps) from acquisition and pre-approval launch timing, freight/fuel cost pressure, payer coverage timing for new products, and the need to refinance a sizable convertible in 2028. On balance, the positive growth, margin recovery plans, product launches, and improved cash flow prospects outweigh the near-term headwinds.View all CH:NG9 earnings summariesNG9 Stock 12 Month Forecast
Average Price Target
CHF12.12
Options Prices
Currently, No data available
---